Regulation
Sonorous wins FDA IDE for pulsatile tinnitus stent pivotal trial initiation
Sonorous Medical received FDA Investigational Device Exemption (IDE) approval to initiate a pivotal trial for BosSTENT, a stent designed to treat pulsatile tinnitus. The device previously earned FDA breakthrough device designation in February 2026, expediting its development pathway toward potential market clearance.
The source
This brief is a MedIndexer summary of reporting by Medical Device Network. To read the full story, head to the source.
Read the full story at Medical Device Network